Prothrombotic Phenotype in COVID-19: Focus on Platelets.

Area of Science:

• Hematology
• Immunology
• Pathology

Background:

• COVID-19 presents with diverse symptoms, including microthrombi in alveolar capillaries.
• These microthrombi result from severe endothelial injury and indicate COVID-19-associated coagulopathy.
• Coagulopathy contributes to thrombosis, organ damage, and mortality in COVID-19 patients.

Purpose of the Study:

• To investigate the role of platelet activation in COVID-19 coagulopathy.
• To understand the link between viral-mediated endothelial inflammation and prothrombotic abnormalities.
• To identify potential biomarkers for severe COVID-19 progression.

Main Methods:

• Analysis of coagulation alterations in COVID-19 patients.
• Examination of platelet function and inflammatory mediator release.
• Correlation of platelet activation markers with disease severity and outcomes.

Main Results:

• Platelet activation and viral-mediated endothelial inflammation are central to COVID-19 coagulopathy.
• Platelets modulate immune response and contribute to acute lung injury via cytokine release and NET formation.
• Elevated platelet factor 4 deposition is linked to neutrophil adhesion and thrombogenesis.

Conclusions:

• Platelet hyperactivation, cytokine storm, and specific biomarker levels (e.g., P-selectin, D-dimer) characterize severe COVID-19.
• These findings highlight platelets as crucial players in COVID-19 pathogenesis and severity.
• Biomarker profiles may aid in distinguishing late-stage COVID-19 in critically ill patients.